Phenomix Grants Chiesi Farmaceutici European Rights to Dutogliptin for Diabetes
SAN DIEGO & PARMA, Italy–(BUSINESS WIRE)–Phenomix Corporation and Chiesi Farmaceutici today announced that they have entered into a definitive agreement to develop and commercialize dutogliptin (PHX1149) in Europe and additional territories including Brazil, Russia and all other members of the Commonwealth of Independent States (“CIS”), Turkey and Northern Africa. Dutogliptin is Phenomix’ proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor
Read the rest here:
Phenomix Grants Chiesi Farmaceutici European Rights to Dutogliptin for Diabetes

